Molecular Pathology v. Myriad Genetics: The Implications of the Supreme Court Decision
$175
About the Course
In Molecular Pathology v. Myriad Genetics, the Supreme Court held that isolated DNA is not patent-eligible subject matter, but that cDNA may be patent-eligible subject matter under certain circumstances.
This webinar discusses the extent to which additional limitations may be placed on the patentability of biotechnology claims.
Among additional issues discussed during this webinar are:
- •How will the Myriad decision impact the “law of nature” exceptions?
- •What are some of the limitations to the Myriad decision?
- •According to the Myriad decision, what is the distinction between “invention” and “discovery”?
- •How does the Myriad decision differ from the Mayo decision?
- •Why is it that, because of the Myriad decision, the better targeted personal medicine becomes, the less patent-eligible it will become?
- •What are potential variations of post-Myriad legislation and how might such legislation affect life sciences patents?
- •What is the history of the Court of Appeals for the Federal Circuit?
- •What is the disposition of newly appointed Supreme Court justices toward patents?
- •What is the proclivity of the Supreme Court to rely on decisions from foreign jurisdictions?
- •How influential are Amicus Curiae briefs on Supreme Court justices?
- •To what extent should decisions relating to plant patents be reviewed in divining the direction of life science patent jurisprudence?
Course Leader
Gregory A. Castanias, Partner, Jones Day
Greg Castanias is an appellate and intellectual property litigator with extensive Supreme Court and Federal Circuit advocacy experience and heads Jones Day’s Federal Circuit practice.
His experience includes multiple arguments before the U.S. Supreme Court and more than 40 arguments and approximately 150 appearances before the Federal Circuit, including many of the most pathbreaking cases in recent years.
Greg has represented clients including Abbott, Apple, IBM, Illumina, LabCorp, Myriad Genetics, Pfizer, Procter & Gamble, SAP, SAS Institute, and Visa, among many others.
Course Length
Approx. 1.0 hours
Pricing
$175 per user